Evaluating cirrhosis and respiratory syncytial virus infection: Should we vaccinate?

doi:10.4254/wjh.v18.i3.114519

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(36)

(41)

(0)

(709)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Mar 27, 2026; 18(3): 114519
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.114519

Table 3 Characteristics of patients hospitalised with and without respiratory syncytial virus, n (%)/median (interquartile range)

	RSV+	RSV-	P value
Age, years	78 (71-85)	68 (56-79)	< 0.001
Sex (female)	58 (53.2)	22879 (46.1)	0.163
Cirrhosis	2 (1.8)	742 (1.5)	1.000
Ischaemic heart disease	10 (9.2)	7306 (14.7)	0.135
Congestive heart failure	29 (26.6)	5522 (11.1)	< 0.001
COPD	24 (22.0)	3222 (6.5)	< 0.001
Chronic kidney disease	17 (15.6)	2573 (5.2)	< 0.001
Obesity	0 (0.0)	1089 (2.2)	0.217
Diabetes	63 (57.8)	33539 (67.6)	0.039

From a cohort of patients with specific chronic health conditions (n = 49758), 109 with respiratory syncytial virus. RSV: Respiratory syncytial virus; COPD: Chronic obstructive pulmonary disease.

Full Size Table

Citation: Walia N, Lu I, Hannah N, Sood S. Evaluating cirrhosis and respiratory syncytial virus infection: Should we vaccinate? World J Hepatol 2026; 18(3): 114519
URL: https://www.wjgnet.com/1948-5182/full/v18/i3/114519.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i3.114519

Walia N, Lu I, Hannah N, Sood S. Evaluating cirrhosis and respiratory syncytial virus infection: Should we vaccinate? World J Hepatol 2026; 18(3): 114519 [DOI: 10.4254/wjh.v18.i3.114519]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.